Purchase Order 75N92019P00413
Award Date
9/18/19
Potential Completion Date
3/17/20
Potential Value
$102K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Pharmaron, Inc.
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $113,400 contract is part of the NIH Bioanalysis Testing Services 2015-2020 IDIQ (Indefinite Delivery/Indefinite Quantity) vehicle. The work involves conducting pharmacokinetic assessments, toxicity studies, and ion channel testing services to support drug discovery and development efforts, including evaluating...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $108,000 purchase order to Pharmaron, Inc. for pharmacokinetics experiments involving forty rodents across two study arms. The one-year contract has Pharmaron performing the work in China under a firm fixed price arrangement. No additional details were provided on subcontractors or the specific NIH programs the research aims to support. The award information...
This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
This firm fixed price purchase order for $78,300 was awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Pharmaron, Inc. for testing of compounds in cardiac ion channel assays. Pharmaron, a minority-owned small business, will conduct the ion channel testing at its division location in China to help advance potential new therapies through the drug development process, in line with NCATS' mission. No...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Pharmaron, Inc. for $149,520.00. The award is under the NIH Bioanalysis Testing Services 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract vehicle. Pharmaron, a minority-owned, for-profit contract research organization (CRO), will provide pharmacokinetics assessments, toxicity studies, and ion channel testing...
This federal contract award was issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a global contract research organization. The $87,805.00 firm fixed price contract was awarded as a delivery order under the NIH Bioanalysis Testing Services 2015-2020 master contract vehicle. Under this contract, Pharmaron conducted various drug development activities for NCATS, including...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. for $24,624.00. The contract is to obtain pharmacokinetic exposure data from mouse PK studies and plasma protein binding assays, which are common preclinical services provided by Pharmaron, a global contract research organization (CRO) specializing in drug discovery and development. This contract...
This firm fixed-price purchase order, valued at $78,300.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned, for-profit organization classified as a Subcontinent Asian (Asian-Indian) American owned business. The contract is for the testing of compounds to block cardiac ion channels, with a period of performance ending on November 16, 2022. Pharmaron, a global contract research organization (CRO) specializing...
This is a $78,300.00 firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned for-profit organization. The contract is for testing compounds for the blockage of cardiac ion channels, which is a critical step in the drug development process. As a global contract research organization (CRO), Pharmaron has extensive expertise in preclinical research services, including...